{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:50:09Z","timestamp":1761749409579,"version":"build-2065373602"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.path.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:12:54Z","timestamp":1558609974000},"page":"651-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"12","author":[{"given":"Sanam","family":"Loghavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib1","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.path.2019.03.010_bib2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2006-03-008227","article-title":"The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib5","first-page":"719","article-title":"Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"91","author":"Remacha","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib6","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib7","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"Broseus","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/10428194.2015.1045895","article-title":"Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"57","author":"Visconte","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.path.2019.03.010_bib10","series-title":"WHO classification of tumours of haematopoietic and lymhoid tissues","first-page":"82","article-title":"Chronic myelomonocytic leukemia","author":"Orazi","year":"2017"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","article-title":"The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands","volume":"39","author":"Dinmohamed","year":"2015","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.path.2019.03.010_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V63.3.634.634","article-title":"Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases","volume":"63","author":"Solal-Celigny","year":"1984","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-015-0271-4","article-title":"Chronic myelomonocytic leukemia: a genetic and clinical update","volume":"10","author":"McCullough","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib15","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ajh.24267","article-title":"Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2006.00652.x","article-title":"The results of imatinib therapy for patients with primary eosinophilic disorders","volume":"76","author":"Helbig","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.path.2019.03.010_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-7-26","article-title":"Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia","volume":"7","author":"Shah","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2019.03.010_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume":"85","author":"Hu","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.13529","article-title":"TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis","volume":"171","author":"Loghavi","year":"2015","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.path.2019.03.010_bib21","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","article-title":"Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories","volume":"2","author":"Loghavi","year":"2018","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.path.2019.03.010_bib22","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2009-05-224352","article-title":"Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia","volume":"115","author":"Droin","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.path.2019.03.010_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/cup.13039","article-title":"Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia","volume":"44","author":"Loghavi","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ejh.12477","article-title":"Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response","volume":"95","author":"Shen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.path.2019.03.010_bib27","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib28","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1038\/bcj.2017.66","article-title":"Flow\u00a0cytometry based monocyte subset analysis accurately\u00a0distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis","volume":"7","author":"Patnaik","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.path.2019.03.010_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.path.2019.03.010_bib31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.path.2019.03.010_bib32","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib33","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2019.03.010_bib34","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.23652","article-title":"BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS","volume":"89","author":"Zhang","year":"2014","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.path.2019.03.010_bib37","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.path.2019.03.010_bib38","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.path.2019.03.010_bib40","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2019.03.010_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.leukres.2018.05.012","article-title":"Characterization of chronic myelomonocytic leukemia with TP53 mutations","volume":"70","author":"Wang","year":"2018","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.path.2019.03.010_bib42","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib43","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic\u00a0factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.path.2019.03.010_bib47","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/1078-0432.CCR-16-0372","article-title":"Unplugging JAK\/STAT in chronic myelomonocytic leukemia","volume":"22","author":"Solary","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2019.03.010_bib48","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"80","article-title":"Atypical chronic myeloid leukaemia, BCR-ABL1 negative","author":"Vardiman","year":"2008"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11899-016-0350-1","article-title":"An exercise in extrapolation: clinical management of atypical CML, MDS\/MPN-unclassifiable, and MDS\/MPN-RS-T","volume":"11","author":"Talati","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"17","key":"10.1016\/j.path.2019.03.010_bib50","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib51","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.path.2019.03.010_bib52","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3109\/10428194.2012.762648","article-title":"A\u00a0BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib53","first-page":"218","article-title":"Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene","volume":"35","author":"Bellesso","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/BF02982694","article-title":"Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions","volume":"76","author":"Muta","year":"2002","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.path.2019.03.010_bib57","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.path.2019.03.010_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ijlh.12509","article-title":"Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic\/myeloproliferative neoplasms: current diagnostic principles and upcoming updates","volume":"38","author":"Geyer","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"20","key":"10.1016\/j.path.2019.03.010_bib59","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3349\/ymj.2014.55.3.753","article-title":"Delta neutrophil index as an early marker for differential diagnosis of adult-onset Still's disease and sepsis","volume":"55","author":"Park","year":"2014","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/qjmed\/hcm006","article-title":"Extreme leukocytosis in the emergency department","volume":"100","author":"Lawrence","year":"2007","journal-title":"QJM"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib62","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1572-0241.1998.1013a.x","article-title":"Severe leukocytosis with neutrophilia (leukemoid reaction) in alcoholic steatohepatitis","volume":"93","author":"Juturi","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.arcmed.2004.02.001","article-title":"Smoking-induced leukocytosis can persist after cessation of smoking","volume":"35","author":"Kawada","year":"2004","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2249.2005.02829.x","article-title":"Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases","volume":"141","author":"Biezeveld","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib65","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ajcp\/109.6.675","article-title":"Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor","volume":"109","author":"Meyerson","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1172\/JCI108159","article-title":"Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone","volume":"56","author":"Dale","year":"1975","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00043426-198722000-00005","article-title":"Exercise-induced changes in the blood concentration of leukocyte populations in teenage athletes","volume":"9","author":"Christensen","year":"1987","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archinte.158.3.300","article-title":"Extreme leukemoid reaction associated with retroperitoneal hemorrhage","volume":"158","author":"Marinella","year":"1998","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/1097-0142(19870815)60:4<903::AID-CNCR2820600431>3.0.CO;2-6","article-title":"Leukocytosis and large cell lung cancer. A frequent association","volume":"60","author":"Ascensao","year":"1987","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib70","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2169\/internalmedicine.32.869","article-title":"Leukemoid reaction associated with diabetic ketoacidosis\u2014with measurement of plasma levels of granulocyte colony-stimulating factor","volume":"32","author":"Kayashima","year":"1993","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib71","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1080\/10428190310001645870","article-title":"Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia","volume":"45","author":"Kohmura","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s11899-017-0413-y","article-title":"Recent progress in chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"12","author":"Dao","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hernandez","year":"2000","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib74","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.path.2019.03.010_bib75","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.path.2019.03.010_bib76","series-title":"WHO classification of tumours of haematopietic and lymphoid tissues","first-page":"93","article-title":"Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","author":"Orazi","year":"2017"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib77","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.path.2019.03.010_bib78","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.path.2019.03.010_bib79","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.seminhematol.2009.07.001","article-title":"Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment","volume":"46","author":"Camaschella","year":"2009","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.path.2019.03.010_bib84","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2019.03.010_bib85","first-page":"2273","article-title":"Therapeutic approaches in myelofibrosis and myelodysplastic\/myeloproliferative overlap syndromes","volume":"9","author":"Sochacki","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"19","key":"10.1016\/j.path.2019.03.010_bib86","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib87","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.path.2019.03.010_bib88","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.path.2019.03.010_bib89","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A\u00a0phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.path.2019.03.010_bib91","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Broseus","year":"2013","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.path.2019.03.010_bib92","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","article-title":"SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes","volume":"120","author":"Visconte","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2019.03.010_bib93","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.path.2019.03.010_bib94","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib95","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.path.2019.03.010_bib97","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2010-12-324715","article-title":"Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib98","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","article-title":"The JAK2 V617F mutation identifies a subgroup of MDS\u00a0patients with isolated deletion 5q and a proliferative bone marrow","volume":"20","author":"Ingram","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.path.2019.03.010_bib99","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.path.2019.03.010_bib100","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.leukres.2009.09.016","article-title":"JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones","volume":"34","author":"Sokol","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.path.2019.03.010_bib101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.path.2019.03.010_bib102","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy-related chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib104","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2019.03.010_bib105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","article-title":"Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series\u00a0of 133 patients","volume":"75","author":"Visani","year":"1990","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.path.2019.03.010_bib106","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.path.2019.03.010_bib107","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00277-017-3211-7","article-title":"Bone marrow findings in blast phase of polycythemia vera","volume":"97","author":"Hidalgo Lopez","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Fu","year":"2014","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.path.2019.03.010_bib110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2019.03.010_bib111","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.path.2019.03.010_bib112","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918119300273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918119300273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:41:42Z","timestamp":1761748902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918119300273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1875918119300273"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2019.03.010","relation":{},"ISSN":["1875-9181"],"issn-type":[{"type":"print","value":"1875-9181"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}